{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:46:58Z","timestamp":1788292018191,"version":"build-2803163510"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Sotagliflozin (trade name INFEPA) is a novel dual sodium-glucose cotransporter-1 and -2 (SGLT-1\/2) inhibitor that was developed by Lexicon Pharmaceuticals. It has emerged as a promising therapy for managing heart failure and other cardiovascular complications associated with type 2 diabetes mellitus (T2DM). Its dual inhibition of SGLT-1 and SGLT-2 receptors uniquely decreases glucose absorption in the intestine in addition to decreasing renal glucose reabsorption, leading to improved glycemic control and cardio-reno protection. Clinical trials have demonstrated its efficacy in reducing cardiovascular death, heart failure hospitalizations, and urgent visits, particularly in T2DM patients with chronic kidney disease (CKD). The drug was approved in 2023 by the Food and Drug Administration for reducing cardiovascular death and heart failure in T2DM patients with CKD and those with heart failure, irrespective of diabetic status or ejection fraction. However, despite its considerable therapeutic potential, sotagliflozin does pose notable adverse effects, including diabetic ketoacidosis, genital infections, and diarrhea. As a result, it has faced regulatory challenges in certain regions, notably the United States. The Food and Drug Administration has so far withheld approval for sotagliflozin in the treatment of type 1 diabetes due to concerns about its safety profile, specifically the risk of diabetic ketoacidosis, although Lexicon Pharmaceuticals plans to submit another new drug application for this use in 2024. Further investigation and clinical trials are warranted to fully elucidate sotagliflozin\u2019s impact on diabetes and CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/crd.0000000000000760","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T09:04:03Z","timestamp":1722243843000},"page":"378-384","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["A Review of Sotagliflozin: The First Dual SGLT-1\/2 Inhibitor"],"prefix":"10.1097","volume":"34","author":[{"given":"Zoya","family":"Siddiqui","sequence":"first","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloofar","family":"Rasouli","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Felder","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY"},{"name":"Departments of Medicine and Cardiology, Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"R1-20260605","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3390\/endocrines4030045","article-title":"Exploring SGLT-2 inhibitors: benefits beyond the glucose-lowering effect\u2014what is new in 2023?","volume":"4","author":"Young","year":"2023","journal-title":"Endocrines"},{"key":"R2-20260605","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","article-title":"Dapagliflozin: a review in type 2 diabetes.","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"R4-20260605","doi-asserted-by":"crossref","first-page":"9852","DOI":"10.3390\/ijms22189852","article-title":"Effects of SGLT2 inhibitors beyond glycemic control-focus on myocardial SGLT1.","volume":"22","author":"Sayour","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R5-20260605","doi-asserted-by":"crossref","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","article-title":"SGLT-2 inhibitors in heart failure: a review of current evidence.","volume":"5","author":"Talha","year":"2023","journal-title":"Int J Heart Fail"},{"key":"R6-20260605","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/17512433.2021.1908123","article-title":"Sotagliflozin and decompensated heart failure: results of the SOLOIST-WHF trial.","volume":"14","author":"Shah","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R8-20260605","first-page":"100130","article-title":"Managing heart failure in diabetics with dual acting sotagliflozin\u2014a review.","volume":"9","author":"Seni","year":"2023","journal-title":"Health Sci Rev"},{"key":"R9-20260605","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s40265-019-01146-5","article-title":"Sotagliflozin: first global approval.","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"R11-20260605","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American intandem1 study.","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"key":"R13-20260605","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1479164114563304","article-title":"Development of sotagliflozin, a dual sodium-dependent glucose transporter 1\/2 inhibitor.","volume":"12","author":"Lapuerta","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"R14-20260605","first-page":"e45525","article-title":"Sotagliflozin vs dapagliflozin: a systematic review comparing cardiovascular mortality.","volume":"15","author":"Iyer","year":"2023","journal-title":"Cureus"},{"key":"R15-20260605","doi-asserted-by":"crossref","first-page":"115263","DOI":"10.1016\/j.bmc.2019.115263","article-title":"Anti-diabetic drugs recent approaches and advancements.","volume":"28","author":"Dowarah","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"R16-20260605","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/jdi.13255","article-title":"Sodium-glucose cotransporters: functional properties and pharmaceutical potential.","volume":"11","author":"Sano","year":"2020","journal-title":"J Diabetes Investig"},{"key":"R17-20260605","doi-asserted-by":"crossref","first-page":"100089","DOI":"10.1016\/j.metop.2021.100089","article-title":"Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: in the heart of the problem.","volume":"10","author":"Vallianou","year":"2021","journal-title":"Metabol Open"},{"key":"R18-20260605","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12933-019-0828-y","article-title":"Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.","volume":"18","author":"Cefalo","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"R19-20260605","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"HbA.","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care"},{"key":"R20-20260605","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes.","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"key":"R21-20260605","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2337\/dc14-2806","article-title":"Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes.","volume":"38","author":"Sands","year":"2015","journal-title":"Diabetes Care"},{"key":"R22-20260605","doi-asserted-by":"crossref","first-page":"l1328","DOI":"10.1136\/bmj.l1328","article-title":"Efficacy and safety of dual SGLT 1\/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.","volume":"365","author":"Musso","year":"2019","journal-title":"BMJ"},{"key":"R23-20260605","doi-asserted-by":"crossref","first-page":"2042018819890527","DOI":"10.1177\/2042018819890527","article-title":"A review of sotagliflozin for use in type 1 diabetes.","volume":"10","author":"Nuffer","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"R24-20260605","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/dom.14006","article-title":"Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity.","volume":"22","author":"Yokote","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"R25-20260605","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1111\/dom.14495","article-title":"Licogliflozin versus placebo in women with polycystic ovary syndrome: a randomized, double-blind, phase 2 trial.","volume":"23","author":"Tan","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"R26-20260605","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.2147\/DMSO.S240903","article-title":"SGLT2 inhibitors in the management of type 1 diabetes (T1D): an update on current evidence and recommendations.","volume":"16","author":"Maffei","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R28-20260605","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"R29-20260605","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"R30-20260605","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R31-20260605","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"R32-20260605","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"R33-20260605","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/dom.14555","article-title":"Sotagliflozin for patients with type 2 diabetes: a systematic review and meta-analysis.","volume":"24","author":"Avgerinos","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"R34-20260605","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"R35-20260605","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"R36-20260605","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"R37-20260605","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease.","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"R38-20260605","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure.","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"R39-20260605","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.7326\/M21-0651","article-title":"Effect of sotagliflozin on total hospitalizations in patients with type 2 diabetes and worsening heart failure: a randomized trial.","volume":"174","author":"Szarek","year":"2021","journal-title":"Ann Intern Med"},{"key":"R40-20260605","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2215\/CJN.0000000000000414","article-title":"Sotagliflozin and kidney outcomes, kidney function, and albuminuria in type 2 diabetes and CKD: a secondary analysis of the SCORED trial.","volume":"19","author":"Sridhar","year":"9900","journal-title":"Clin J Am Soc Nephrol"},{"key":"R41-20260605","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease.","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"R43-20260605","doi-asserted-by":"crossref","first-page":"e1235","DOI":"10.1210\/clinem\/dgz258","article-title":"Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption.","volume":"105","author":"Powell","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R44-20260605","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis.","volume":"100","author":"Taylor","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 2","key":"R45-20260605","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/dom.13630","article-title":"What does sodium-glucose co-transporter 1 inhibition add: prospects for dual inhibition.","volume":"21","author":"Dominguez Rieg","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R46-20260605","doi-asserted-by":"crossref","first-page":"1373314","DOI":"10.3389\/fphar.2024.1373314","article-title":"Sotagliflozin versus dapagliflozin to improve outcome of patients with diabetes and worsening heart failure: a cost per outcome analysis. Original Research.","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Pharmacol"},{"key":"R47-20260605","doi-asserted-by":"crossref","first-page":"e32489","DOI":"10.1097\/MD.0000000000032489","article-title":"Clinical efficacy of SGLT2 inhibitors with different SGLT1\/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: a systematic review and meta-analysis of randomized trials.","volume":"101","author":"Lee","year":"2022","journal-title":"Medicine (Baltim)"},{"key":"R48-20260605","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.2337\/dc21-2166","article-title":"Metabolic, intestinal, and cardiovascular effects of sotagliflozin compared with empagliflozin in patients with type 2 diabetes: a randomized, double-blind study.","volume":"45","author":"Posch","year":"2022","journal-title":"Diabetes Care"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:00:16Z","timestamp":1780671616000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000760","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]}}}